Evaluating the best treatment for multifocal hepatocellular carcinoma: A propensity score-matched analysis

Table 3 Liver function test and disease burden after propensity score matching (n = 30)

	Resection, n = 15	TACE, n = 15	Total, n = 30	P value
INR	1.2 ± 0.1	1.3 ± 0.3	1.2 ± 0.2	0.185
Bilirubin (mg/dL)	0.75 ± 0.5	1.2 ± 0.6	0.99 ± 0.6	0.026
Platelets (103/μL)	245 ± 118	95 ± 31	163 ± 111	0.003
Creatinine (mg/dL)	1.37 ± 0.8	0.78 ± 0.2	1.08 ± 1.19	0.188
AFP, n (%)				1.000
< 400 ng/mL	13 (86.7)	12 (80)	25 (83.3)
> 400 ng/mL	2 (13.3)	3 (20)	5 (16.7)
Varices, n (%)				0.081
No	8 (80)	4 (36.4)	12 (57.1)
Yes	2 (20)	7 (63.6)	9 (42.9)
Missing	5	4	9
Cirrhosis, n (%)				0.100
No	4 (26.7)	0	4 (13.3)
Yes	11 (73.3)	15 (100)	26 (86.7)
Child-Pugh score, n (%)				0.556
A5	8 (53.3)	5 (33.3)	13 (43.3)
A6	6 (40)	7 (46.7)	13 (43.3)
B7	1 (6.7)	3 (20)	4 (13.4)
MELD score	9.1 ± 3.2	9.9 ± 2.4	9.5 ± 2.8	0.473
Number of lesions	2 (2-5)	3 (2-5)	2 (2-5)	0.101
Diameter (mm)	46.3 ± 3	47 ± 5	46.9 ± 12.9	0.793
Up-to-7 criteria, n (%)				0.456
In	10 (66.7)	8 (53.3)	18 (60)
Out	5 (33.3)	7 (46.7)	12 (40)
ITA.LI.CA classification, n (%)				0.868
B1	10 (66.7)	8 (53.3)	18 (60)
B2	3 (20)	5 (33.3)	8 (26.7)
B3	2 (13.3)	2 (13.3)	4 (13.3)

TACE: Trans-Arterial ChemoEmbolization; INR: International normalized ratio; AFP: Alpha-fetoprotein; MELD: Model for End-Stage Liver Disease.